Different doses of aminocaproic acid in perioperative bleeding and blood transfusion during cardiopulmonary bypass cardiac surgery: a single-center, prospective, randomized controlled clinical trial

Start Date01 Sep 2024

Sponsor / Collaborator

The Affiliated Hospital of Qingdao University

[+1]

NCT04814433

/ TerminatedPhase 4IIT

A Randomized, Single-Blinded, Placebo-Controlled Study Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

This study is a prospective randomized trial examining the effect of topically combined antifibrinolytics (Tranexamic acid) with local anesthetics in all electively created surgical wound beds in hand surgery to provide long term pain relief and decrease the use of postoperative narcotics.

Start Date24 Mar 2021

Sponsor / Collaborator

NYU Langone Health

ChiCTR2000032271

/ RecruitingNot ApplicableIIT

Epsilon-aminocaproic Acid versus Tranexamic Acid in reducing blood loss in Total Hip/knee Arthroplasty：A Prospective Randomised controlled trial

Start Date30 Apr 2020

Sponsor / Collaborator-

100 Clinical Results associated with Aminocaproic Acid

100 Translational Medicine associated with Aminocaproic Acid

100 Patents (Medical) associated with Aminocaproic Acid

5,347

Literatures (Medical) associated with Aminocaproic Acid

01 Oct 2025·BIOMATERIALS

Acid-responsive contractile hyaluronic acid-based hydrogel loaded with ginsenoside Rg1 for hemostasis and promotion of gastric wound healing

Article

Author: Liu, Bohao ; Tao, Runyi ; Sun, Ye ; Wang, Hongyi ; Wang, Zhiyu ; Guo, Baolin ; Chen, Zhe ; Feng, Jinteng ; Zhang, Guangjian ; Li, Tongyang ; Wang, Jizhao ; Fan, Kun ; Li, Yixing ; He, Jiahui

Due to constant stimulation by stomach acid and local bleeding, gastric tissue wounds tend to heal slowly and complications such as anastomotic leakage have a high incidence. Suturing is often used to treat gastric wounds in clinic, but it still faces risks such as bleeding, slow healing, and leakage. Recently, hydrogel have been widely used to treat various types of wounds. Although hydrogels have shown promising efficacy in wound healing, it is still a challenge in dealing with wounds in gastric tissue for the poor adaptability of traditional materials in acidic environments. Hence, a series of pH responsive and good tissue adhesive hydrogels (MA-HA/AA) based on methacryloyl hyaluronic acid (MA-HA) and acryloyl-6-aminocaproic acid (AA) via in situ photo-crosslinking were designed, and anti-inflammatory and pro-healing traditional Chinese medicines ginsenoside Rg1 was incorporated into the hydrogel to treat gastric tissue wound. These acid-responsive hydrogels could form effective acid-resistant barriers and could lead to hemostasis rapidly through its strong adhesion. Besides, the hydrogels contracted under an acidic environment, which could tighten the gastric tissue wounds and sustained release the loaded ginsenoside Rg1. In addition, the hydrogels showed excellent biocompatibility and in vivo degradability. In summary, the acid-responsive contractile hyaluronic acid hydrogel loaded with ginsenoside Rg1 had good properties for hemostasis and acid-resistance to facilitate the promotion of gastric wounds healing.

01 Oct 2025·CHEMICAL ENGINEERING SCIENCE

Random scission kinetic model for polymer degradation: A case study of polyamide-6 hydrolysis in subcritical water

Author: Yuan, Pei-Qing ; Tan, Xue-Cai ; Shi, Ruo-Fan ; Yang, Jing-Yi ; Li, Yan ; Huang, Zi-Bin ; Lin, Zhuo-Han ; Liu, Ren-Feng

This study investigated the non-catalytic hydrolysis of polyamide-6 (PA6) in subcritical water (Sub-CW) and developed reaction kinetic model based on random chain scission.Mol. dynamics simulations and product characterization reveal that PA6 hydrolysis in Sub-CW occurs not only at the interface but also within the molten PA6.The temporal evolution of the d.p. (DP) distribution of unreacted polymer, governed by random scission, is quant. described using a synergistic approach incorporating binomial scission probabilities and Monte Carlo simulations.Parameter estimation based on exptl. data indicates that the activation energy for water attacking amide bond scission is 130 kJ/mol, while the cyclodehydration of 6-aminohexanoic acid to ε-caprolactam exhibits a reaction enthalpy of 14 kJ/mol.A notable feature of polymer degradation governed by the random scission model is the sharp decline in degradation efficiency as DP decreases, with the majority of reaction time devoted to the conversion of oligomers into monomers.

01 Oct 2025·ADVANCED FUNCTIONAL MATERIALS

Extracorporeal Catalytic Hemoperfusion Therapy for Refractory Septic Shock Using Ceria Nanoparticle‐Embedded Porous Microbeads

Author: Donghee Kim ; Young-Min Kim ; Jaeyun Kim ; Eun-seo Choi ; Jimin Song ; Pilseon Im ; Seo-Hyeon Jeong ; Han-Gil Jeong ; Inwon Park ; Jooho Park ; Ngoc Man Phan

Abstract:

Septic shock is a life‐threatening medical condition characterized by organ dysfunction resulting from a dysregulated host response to infection and marked by rapid, ubiquitous generation of reactive oxygen species (ROS). Although extracorporeal devices can remove pathogenic endotoxins or inflammatory cytokines, it is not yet possible to effectively target the excessive ROS in the blood of patients with sepsis. Here, a novel extracorporeal blood purification system is proposed based on porous microbeads embedded with autocatalytic ceria nanoparticles (CeNPs), as a safer and potentially life‐saving solution for septic shock. Porous microbeads (PMB), consisting of an assembly of mesoporous silica particles, are loaded with a large amount of CeNPs and subsequently coated with polyvinylpyrrolidone, a hydrophilic and blood‐compatible polymer (P‐Ce‐PMB). A hemoperfusion column cartridge composed of P‐Ce‐PMB exhibited effective and durable ROS‐scavenging capability and hemocompatibility, without inducing blood clotting during perfusion. Further, in a refractory septic shock animal model, hemoperfusion through such a cartridge has a 100% survival rate compared to 0% in the standard intensive care group, accompanied by significant improvements in hemodynamic profiles and multiple organ injuries. This study highlights the potential of effective ROS‐scavenging in extracorporeal hemoperfusion as a viable clinical strategy for septic shock therapy.

News (Medical) associated with Aminocaproic Acid

10 Jul 2025

·www.einpresswire.com

Antifibrinolytic Drugs Market to Hit $19.3 Billion by 2026 Amid Rising Demand for Hemorrhage Control

North America accounted for majority of the market share in 2018 and is anticipated to continue this trend during the forecast period. PORTLAND, OR, UNITED STATES, July 10, 2025 / EINPresswire.com / -- The Antifibrinolytic Drugs Market size was estimated at $13.59 billion in 2018 and is expected to hit at $19.33 billion by 2026, registering a CAGR of 4.5% from 2019 to 2026. The report provides a detailed analysis of the market size & estimations, top investment pockets, top winning strategies, drivers & opportunities, competitive scenario, and wavering market trends. ► Don't Miss Out “Download Your Exclusive Sample PDF Report” Now: https://www.alliedmarketresearch.com/request-sample/6279 Antifibrinolytics are one of the most commonly used drugs to prevent fibrinolysis by blocking the activation of plasminogen proenzyme and plasmin. This intervention is critical to avoid clotting in areas that are prone to fibrinolysis such as the oral cavity, nasal cavity and female genitalia. Recommended antifibrinolytic drugs include Epsilon aminocaproic acid, tranexamic acid, Amicar, aminocaproic acid, aprotinin, and Cyklokapron. Also, these drugs find their application in surgery such as heart surgery, neurosurgeries and dental surgery. In addition, women use antifibrinolytic drugs to control heavy menstruation. Major market players covered in the report, such as - Akorn Inc., Aurobindo Pharma Limited, Bayer AG, Ferring Holding SA, Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vitruvias Therapeutics Inc. Key Benefits for Stakeholders - • The report provides quantitative analysis of market segments, current trends, strategies and potential of antifibrinolytic drugs market research to identify potential antifibrinolytic drugs market opportunities in genetics. • In-depth analysis of this sector helps identify current market opportunities. • Market analysis and information related to key drivers, restraints and opportunities are provided. • Porter's Five Forces Analysis identifies the capabilities of buyers and suppliers to enable stakeholders to make profitable business decisions and strengthen the network of buyers. • The largest countries in each region are listed according to their contribution to the global market. • Focusing on market players makes benchmarking easier and provides a clear understanding of the current market situation. • The report includes regional and global antifibrinolytic drugs market analysis, key players, market segments, application areas and Market growth strategies. ★ Procure Complete Report [ 220 Pages PDF with Insights, Charts, Tables, and Figures ] @ https://www.alliedmarketresearch.com/request-for-customization/6279 Antifibrinolytic drugs or agents are used in specific situations or in combination with clotting factor replacement to treat hemophilia. These prevent the breakdown of blood clots by counteracting chemicals in the mucous membrane. Antifibrinolytics are increasingly being used in operations associated with high risk of bleeding. These drugs are useful in the management of optimal coagulation. TABLE OF CONTENT - CHAPTER 1 - INTRODUCTION: 1.1. Report description 1.2. Key market segments 1.3. List of key players profiled in the report 1.4. Research methodology 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models CHAPTER 2 - EXECUTIVE SUMMARY: 2.1. Key findings of the study 2.2. CXO Perspective CHAPTER 3 - MARKET OVERVIEW: 3.1. Market Definition and Scope 3.2. Key Findings 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.3. Market Share Analysis/Top Player Positioning 3.4. Porter’s Five Forces Analysis 3.5. Market Dynamics 3.5.1. Drivers 3.5.2. Restraints 3.5.3. Opportunities… 3.6. COVID-19 Impact Analysis on the market North America accounted for the largest share of the antifibrinolytic drugs market in 2018 and is expected to continue this trend during the forecast period. This is due to the increasing number of women using these drugs to control heavy periods. Additionally, a significant increase in surgeries in this region is driving the market growth. However, the Asia-Pacific region is expected to experience rapid growth due to the rise in road accidents and the increase in the use of these drugs by women to control menstrual cycle. 👉 For Purchase Inquiry of Report: https://www.alliedmarketresearch.com/purchase-enquiry/6279 The antifibrinolytic drugs market is expected to witness a significant growth in the coming years. This market has gained interest of the healthcare and medical sectors owing to increased prevalence of hypertension throughout the globe. Furthermore, the global antifibrinolytic drugs market is segmented on the basis of product type, end user, and region. leading market players have been introducing various strategies to help enterprises move their on-premise models to on-demand models. Frequently Asked Questions? Q1. What is the total market value of antifibrinolytic drugs market report? Q2. Which are the top companies holding the market share in antifibrinolytic drugs market? Q3. Which are the largest regions for this Market? Q4. What is the leading technology of antifibrinolytic drugs market? Q5. What are the major drivers for this specific Market? Q6. What are the upcoming key trends in the antifibrinolytic drugs market report? About Us - Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Pawan Kumar, the CEO of Allied Market Research is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. David Correa Allied Market Research + +1 800-792-5285 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

15 Dec 2023

·synapse.patsnap.com

Understanding Plasminogen activators Inhibitors and Methods to Keep Abreast of Their Recent Developments

Plasminogen activators are enzymes that play a crucial role in the human body's fibrinolytic system. They are responsible for converting plasminogen, an inactive precursor, into plasmin, an active enzyme that breaks down blood clots. Plasminogen activators are essential in maintaining the balance between clot formation and dissolution, preventing excessive clotting and ensuring proper blood flow. They are used therapeutically in the treatment of conditions such as acute ischemic stroke, deep vein thrombosis, and pulmonary embolism, where rapid clot dissolution is necessary. Plasminogen activators, such as tissue plasminogen activator (tPA), are administered intravenously to restore blood flow and prevent tissue damage caused by blood clots. The Plasminogen Activator Inhibitor (PAI) was first discovered in the plasma of pregnant women by Brakman and Astrup in 1963, and subsequently identified by other researchers. Currently, four types of PAIs have been identified in humans: PAI-1, PAI-2, PAI-3, and PAI-4. Among these, PAI-1 accounts for 99% of the activity and plays a major role. PAI-1 is widely distributed in the body’s endothelial cells, smooth muscle cells, liver cells, fat cells, macrophages, neutrophils, glomerular mesangial cells, platelets, and some malignant tumor cells. Plasma PAI-1 is mainly produced by endothelial cells and liver cells. PAI-1 is extremely unstable both in vivo and in vitro, with a half-life of about 20 minutes. This is mainly due to the oxidation of the active center of glutamic acid and the degradation of PAI-1 by cell phagocytosis after forming a complex with tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Plasma PAI-1 mainly exists in two forms: one is active, known as activated PAI-1; the other is inactive, known as latent PAI-1. These two forms of PAI-1 have the same molecular weight and immunoreactivity, but different conformations. The active PAI-1 can be stabilized and maintain its activity by binding to vitronectin. The analysis of the target Plasminogen activators reveals a competitive landscape with companies such as Hunan Er-Kang Pharmaceutical Co., Ltd., Akorn Operating Co. LLC, Hainan Sihuan Pharmaceutical Co. Ltd., and Beijing Science Sun Pharmaceutical Co., Ltd. leading the way with approved drugs. These drugs have been approved for indications such as Conjunctivitis, Hemorrhage, Hordeolum, and more. The development of small molecule drugs and enzymes is progressing rapidly, indicating potential breakthroughs in the treatment of various medical conditions. China is at the forefront of the development of Plasminogen activators, followed by the United States. Other countries/locations are also actively involved in the development of drugs for this target. Overall, the target Plasminogen activators show promise in the pharmaceutical industry, with potential for further growth and development in the future. How do they work?Plasminogen activators inhibitors are substances that inhibit the activity of plasminogen activators. Plasminogen activators are enzymes that convert plasminogen, an inactive precursor, into plasmin, an active enzyme involved in the breakdown of blood clots. Plasminogen activators inhibitors, as the name suggests, prevent or inhibit the activation of plasminogen, thereby reducing the breakdown of blood clots. From a biomedical perspective, plasminogen activators inhibitors play a crucial role in regulating the clotting and fibrinolysis processes in the body. They help maintain the balance between clot formation and clot dissolution. By inhibiting plasminogen activators, these inhibitors can prevent excessive clot breakdown, which may be beneficial in certain medical conditions where clot formation is necessary, such as during surgery or in the treatment of bleeding disorders. In the context of biomedicine, plasminogen activators inhibitors have therapeutic implications. They can be used as medications to prevent the breakdown of blood clots in conditions such as deep vein thrombosis, pulmonary embolism, or stroke. By inhibiting plasminogen activators, these inhibitors can help stabilize blood clots and prevent their dissolution, promoting clot stability and reducing the risk of complications. It is important to note that the use of plasminogen activators inhibitors should be carefully monitored and administered under medical supervision, as their effects on the clotting system need to be balanced to avoid excessive clot formation or inhibition. List of Plasminogen activators InhibitorsThe currently marketed Plasminogen activators inhibitors include: PlasminAminocaproic AcidTaurine/Aminocaproic Acid/Aspartic Acid/Chlorphenamine MaleateTaurine/Aminocaproic Acid/Potassium L-aspartate/Chlorphenamine MaleateLTI-01O2L-001APT-912BM-06021CVS-3083M-5For more information, please click on the image below. What are Plasminogen activators inhibitors used for?Plasminogen activators inhibitors are used therapeutically in the treatment of conditions such as acute ischemic stroke, deep vein thrombosis, and pulmonary embolism, where rapid clot dissolution is necessary. For more information,please click on the image below to log in and search. How to obtain the latest development progress of Plasminogen activators inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of Plasminogen activators inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

07 Dec 2023

·www.fiercepharma.com

FDA posts a flurry of voluntary drug recalls by Teva, Glenmark, Apotex and VistaPharm

VistaPharm, Glemark Pharmaceuticals, Teva and Apotex all issued voluntary recalls posted on the FDA website. The FDA posted a flurry of voluntary drug recalls by drug manufacturers on its website. Below are the companies and products being recalled. VistaPharm issued its Class III recall Oct. 17 for more than 2,300 bottles of aminocaproic acid oral solution that is used to treat serious bleeding conditions, especially when the bleeding occurs after dental surgery or other kinds of surgery. The company cited failed specifications for the action, specifically, a high content of ethylene glycol. Where the product was manufactured was not provided. The bottles were distributed nationwide in the U.S. Class III recalls involve products that violate federal regulations but are unlikely to cause adverse health consequences. Aptotex issued four separate Class II recalls Nov. 1 for more than 149,000 bottles distributed nationwide in the U.S. of prescription-only paroxetine hydrochloride tablets that are used to treat a variety of conditions, including depression, obsessive-compulsive disorder and panic disorder. The company cited failed impurities and/or degradation, out-of-specification results. The products were manufactured at the company’s Toronto production site. A Class II recall is issued with a product has a lower chance of causing major injuries or death, but it is still possible for serious enough adverse events to have irreversible consequences. Glenmark Pharmaceuticals issued two separate Class II recalls for products due to a mislabeling issue involving Indomethacin and Naproxen. The recalls for both were issued Nov. 7. The company recalled 37,200 bottles of Indomethacin, which is a non-steroidal anti-inflammatory used to treat pain and arthritis symptoms. It recalled five lots (no bottle count provided) of Naproxen that is used to reduce fever or relieve mild pain due to headaches and muscle aches and other minor maladies. Both products may have been mislabeled as the other, the company said. The drugs were manufactured at both the Glenmark facility in Goa, India, and the company’s New Jersey facility. Teva issued a Class III recall for one lot of 30 unit-dose packets per carton of testosterone gel due to out-of-specification issues related to viscosity. The product, which was produced at the Teva facility in North Wales, Pennsylvania, is used to treat hypogonadism in men. The recall was issued Nov. 10 for the lot that was distributed nationwide in the U.S.

100 Deals associated with Aminocaproic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
D00160	Aminocaproic Acid	B02AA01	DB00513

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hemorrhage	United States	Hikma Pharmaceuticals USA, Inc.	03 Jun 1964

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02656472 (TXAEACA, CTgov)	Phase 4	Complication of extracorporeal circulation	22	tranexamic acid (Tranexamic Acid Arm)	uuoknttjqt(opexojjjvw) = qvagaovcnk sqhxeldexe (ttspnlbjss, jxnzuxmpxf - tgosxwpvpl) View more	-	22 Oct 2024
				Epsilon Aminocaproic Acid (Epsilon Aminocaproic Acid Arm)	uuoknttjqt(opexojjjvw) = wsemjjlifz sqhxeldexe (ttspnlbjss, frscmemrtz - ywwojlaohm) View more
NCT04814433 (CTgov)	Phase 4	Pain, Postoperative	46	Lidocaine Hydrochloride with Epinephrine+Bupivacaine Hydrochloride with Epinephrine (Topical Lidocaine and Bupivacaine Alone)	stbdmmksbx(qrfunayiqo) = xioygwdhhg cayoihdzfv (oyxgwrrlvs, lduqpekmwk - gdclcrlvqm) View more	-	26 Jun 2024
				Recombinant Human Thrombin+Lidocaine Hydrochloride with Epinephrine+Bupivacaine Hydrochloride with Epinephrine (Topical Lidocaine and Bupivacaine With Thrombin)	stbdmmksbx(qrfunayiqo) = chmbkmqqqs cayoihdzfv (oyxgwrrlvs, uonfhhgiaw - wfpjxdhkgf) View more
NCT02257580 (CTgov)	Phase 4	Hemorrhage	28	E-Aminocaproic acid (E-Aminocaproic Acid (EACA))	zbyvboefgv(vmabkgbhov) = dadqnxplpy sbupbfcuce (axiadljamr, 356.6) View more	-	23 Nov 2022
				E-Aminocaproic acid (Placebo)	zbyvboefgv(vmabkgbhov) = yzvboeipcz sbupbfcuce (axiadljamr, 235.8) View more
NCT02074436 (PROBLEMA, CTgov)	Phase 2	Hemorrhage \| Thrombocytopenia \| Hematologic Neoplasms ... View more	29	EACA (Prophylactic EACA)	nkeizcbqmk = quttnxmceu uoodatqpcz (ikaktkztnl, dzecykylvd - vdeojatcjl) View more	-	19 Jul 2022
				Platelet transfusion (Platelet Transfusion)	nkeizcbqmk = yobcxvjupp uoodatqpcz (ikaktkztnl, syreomqgtt - xjpgiexbou) View more
ISTH2021	Phase 2	-	-	Platelets loaded with EACA	ffvlwzffxx(fvwgenxzkp) = ciryojxuwx loysxewplj (ckewfmrxvm )	-	17 Jul 2021
				Unloaded platelets with free EACA	ffvlwzffxx(fvwgenxzkp) = fwfhadpndv loysxewplj (ckewfmrxvm )
NCT01248104 (CTgov)	Not Applicable	-	100	Tranexamic acid (Tranexamic Acid)	ybdqehokzz(bjdaimddhg) = iwvrtjrjnj xqljastolc (nilrkckujn, 274) View more	-	26 Aug 2020
				Aminocaproic Acid (Aminocaproic Acid)	ybdqehokzz(bjdaimddhg) = vtxuflzshw xqljastolc (nilrkckujn, 296) View more
NCT02655653 (CTgov)	Phase 3	Hemorrhage	114	Epsilon-aminocaproic acid administered (Epsilon-aminocaproic Acid (EACA))	jrbutienud(lklplaqgux) = larjshezzj zklvjuyspv (eiyfwkxthx, 375) View more	-	16 Jun 2020
				Tranexamic Acid administered (Tranexamic Acid (TA))	jrbutienud(lklplaqgux) = twgoghiqux zklvjuyspv (eiyfwkxthx, 400) View more
NCT01398280 (ACA, CTgov)	Early Phase 1	Rosacea	15	Topical aminocaproic acid (ACA) mixed with Vanicream (Aminocaproic Acid (ACA))	lyuicvvgmc(ddyskjkxjm) = mznhayggpz zhimmzhaxc (tmyhnzfjtz, 261.0) View more	-	13 Sep 2019
				Vehicle cream (Vehicle Cream)	lyuicvvgmc(ddyskjkxjm) = huzuekfqfx zhimmzhaxc (tmyhnzfjtz, 422.4) View more
NCT02030821 (CTgov)	Phase 4	Hemorrhage \| Osteoarthritis, Hip \| Osteoarthritis, Knee	246	Amicar	cvfykyzhmj(bowtveyhny) = mkiyygheyg wvttozlbly (zclzhvughm, vrjdejoxzv - staminofie) View more	-	05 Dec 2018
NCT03365999 (Pubmed \| J Arthroplasty)	Phase 2	-	92	Epsilon aminocaproic acid	kxmjexeexk(megwfjnjek) = hogosjhvmf vjbyrxadcj (nkwjfasbts ) View more	Positive	01 Jan 2018
				Epsilon Aminocaproic Acid (Control group)	kxmjexeexk(megwfjnjek) = zfdeetbuwu vjbyrxadcj (nkwjfasbts ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Aminocaproic Acid

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation